The Duke-Margolis Center for Health Policy invites you to a webinar on Monday, June 22, 11:30am-1:30pm EST on Ensuring Sufficient Manufacturing Capacity for COVID-19 Therapeutics.
Many promising treatments for COVID-19 are in development and, if one or more of these treatments prove safe and effective, it will be imperative to be able to manufacture these therapies at scale, to meet extensive world-wide demand. However, scaling up production of these treatments will be challenging because existing manufacturing capacity for a number of the most promising treatments (e.g., monoclonal antibodies and other biologics) is already limited. The United States already faces ongoing shortages of many critical drug products, and the need for additional production will strain our existing capacity even further.
This webinar will explore strategies and policies to ensure sufficient manufacturing capacity for biologic COVID-19 therapeutics. Discussion will address efforts to assess capacity, repurpose existing manufacturing capacity, and develop new manufacturing capacity.
The webinar will feature results of a global survey conducted by the Biotechnology Innovation Organization (BIO), in partnership with the Boston Consulting Group (BCG), on current manufacturing needs and capacity. It will also provide an overview of biologic manufacturing capacity using proprietary bioTRAK® database.